Saturday, December 20, 2014

Season’s Greetings (and JPM 2015)

Season’s Greetings (and JPM 2015)

December 19, 2014 by · Leave a Comment 

Tweet Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be back in full swing with our next Tuesday Feature on […]

LED Medical’s meteoric rise in dental imaging

LED Medical’s meteoric rise in dental imaging

December 16, 2014 by · Leave a Comment 

Tweet With a growing portfolio of digital imaging technology products for the dental sector, LED Medical Diagnostics (OTCQX:LEDIF; TSX-V:LMD; FSE:LME) is positioned to become a leading player in the North American market. “We are in the right space at the right time,” CEO, Dr. David Gane, says in an interview with BioTuesdays.com. “There is an […]

Avivagen’s OxC-beta as natural alternative to antibiotics

Avivagen’s OxC-beta as natural alternative to antibiotics

December 9, 2014 by · Leave a Comment 

Tweet Three peer-reviewed research papers published this year by Avivagen (TSX-V:VIV) and independent collaborators, backed up with successful testing in Asia, have put the company in a position to pursue major contracts for its OxC-beta feed supplement as a natural alternative to antibiotics for the livestock industry. “In OxC-beta, we have discovered a natural alternative […]

Nuvo Research to release Phase 2 WF10 data in Q1

Nuvo Research to release Phase 2 WF10 data in Q1

December 2, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing treatment for moderate-to-severe allergies. “We are targeting a large unmet medical need among some 10 million people in the U.S. who […]

Ruthigen nears clinical milestone with anti-infective drug

Ruthigen nears clinical milestone with anti-infective drug

November 25, 2014 by · Leave a Comment 

Tweet Ruthigen (NASDAQ:RTGN) expects to complete enrollment at the end of the year of the first 20 patients, representing the first arm of the Phase 1/2 clinical trial of RUT58-60, which is intended for use as an adjunct to systemic antibiotics in abdominal surgery. “The medical community, government and society are heightened to the risks […]

Tandem takes consumer device approach to insulin pumps

Tandem takes consumer device approach to insulin pumps

November 18, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=qMfQNC0MqbI&list=PLaVPFQzKqgRmCoJ4T6oNF7v3EWcnDCobu’]

Tweet Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to the design of its products. “When we started the company, we had to figure out why only 27% of people with Type […]

rEVO Biologics spearheading preeclampsia treatment

rEVO Biologics spearheading preeclampsia treatment

November 11, 2014 by · Leave a Comment 

Tweet Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the second quarter of 2016. “This is a potentially life threatening disorder of pregnancy and a devastating unmet medical need,” Yann Echelard, president and […]

CytoTools awaiting India clearance for DermaPro

CytoTools awaiting India clearance for DermaPro

November 4, 2014 by · Leave a Comment 

Tweet CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to treat diabetic foot wounds, thus paving the way to a market launch in early 2015. “Our Phase 3 results in India confirm previous studies and represent […]

AD focus shifts to treating agitation/aggression

AD focus shifts to treating agitation/aggression

October 28, 2014 by · Leave a Comment 

Tweet After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric symptoms associated with AD, such as agitation and aggression. A case in point is Avanir Pharmaceuticals (NASDAQ:AVNR), which reported positive results in mid-September from a Phase […]

Stellar Biotechnologies harvests mollusks for KLH protein

Stellar Biotechnologies harvests mollusks for KLH protein

October 21, 2014 by · Leave a Comment 

Tweet A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) has pioneered technology to grow the mollusk, known as the Giant Keyhole Limpet, and produce and purify KLH, or keyhole limpet hemocyanin, […]

Next Page »

Email Newsletters with Constant Contact
Google+